Investors | Generate:Biomedicines

Skip to content

Announcement: Select Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update

Blog Post: Designing Beyond Tolerability Limits: Advancing GB-4362 Into Clinical Development

Generative Biology®
The Generate Platform™
Pipeline
About Us
Careers
Media Center
Investors

Generative Biology®
The Generate Platform™
Pipeline
About Us
Careers
Media Center
Investors

LinkedIn
X
YouTube

Now we can.

Generate:Biomedicines
101 South Street, Suite 900
Somerville, MA 02143
United States

© 2026 Generate:Biomedicines

LinkedIn
X
YouTube

Privacy Policy
Terms of Use
Cookie Settings